Entity Setup
Entity Setup & Corporate Incentives: Taking Advantage of Japan’s New R&D and Capital Investment Tax Measures
Companies restructuring or investing now can access powerful new tax credits and incentives introduced in Japan’s 2026 reforms—if they align with eligibility criteria.
By NomadicTax Research Team • 5-8 min read • August 12, 2026
## Introduction
Japan’s FY2026 tax reform introduces major new incentives for corporations investing in productivity, research & development (R&D), and asset upgrades. This article explains how to structure entities, plan investment, and satisfy reporting requirements to maximize benefits. Relevant for startups, multinational subsidiaries, manufacturing firms and those with overseas R&D functions.
## Key Corporate Incentives in 2026 Reforms
- **Bold Large-Scale Capital Investment Incentives**: For production equipment etc., companies whose **investment plan** is approved by the Ministry of Economy, Trade and Industry (METI), acquiring “specific productivity improvement equipment” is eligible for **immediate depreciation or a tax credit of 7%** (4% for buildings/structures). Conditions include a plan showing an expected annual investment return rate of 15% or more; large-scale acquisition cost thresholds apply (e.g. ¥3.5 billion+ for general firms, ¥500 million+ for small/medium firms). ([mof.go.jp](https://www.mof.go.jp/tax_policy/tax_reform/outline/fy2026/08taikou_gaiyou.htm?utm_source=openai))
- **Research & Development Tax Credit Expansion**: New “strategic technology area” category established, covering **AI, quantum, bio** etc. Tax credits of **40%** on R&D expenses; for joint or contract research via specified institutions, up to **50%**. For overseas-based outsourced R&D (excluding clinical trials), credits are **50%**, temporarily 70% for FY2026. Credit caps now include carry-forward options up to three years. ([mof.go.jp](https://www.mof.go.jp/tax_policy/tax_reform/outline/fy2026/08taikou_gaiyou.htm?utm_source=openai))
- **Review/Pending Abolitions**: Large-enterprise “wage-increase” credit is being abolished as of March 31, 2026. Local revitalization tax credits (企業版ふるさと納税) extended under strict conditions; medium/larger firms see stricter eligibility. ([mof.go.jp](https://www.mof.go.jp/tax_policy/tax_reform/outline/fy2026/08taikou_gaiyou.htm?utm_source=openai))
## Entity Structuring Best Practices
- **Qualification via METI**: Large capital investment incentives require METI’s approval ahead of investment. Firms should prepare investment plans ahead, with data supporting rate of return, timelines, and business impact.
- **Locating for R&D**: To qualify for overseas outsourced R&D credits, ensure appropriate contracts, documentation, and that the institution meets governmental recognition. Clinical trials still excluded from the highest rate.
- **Choosing between depreciation vs. credit**: For large capital investment, immediate depreciation might give faster cash flow benefit; credit may yield lower taxes over multiple years. Evaluate cash-flow, interest rates, and profitability.
- **Carryforward benefits**: If credits exceed tax liability in a year, under new rules, excess can be **carried forward up to 3 years** under certain certified plans. Plan year-by-year to avoid waste.
## Example: Setting up a Tech Startup in Osaka
Suppose your startup develops a quantum computing platform. You plan to build a lab (¥4 billion) and outsource overseas chip-testing research work.
- Ensure your R&D partner qualifies under the “strategic technology area” and contracts are documented.
- For lab building that counts as “building/structure”, you’ll get 4% tax credit; equipment gets 7%.
- METI approval of your investment plan could make both eligible.
- If your tax liability is small in year 1, claim as much credit as allowed, and carry forward excess for up to 3 years where applicable.
## Compliance and Pitfalls
- Keep **thorough documentation**: contracts, METI approvals, constitution of research institution, proof of overseas subcontracting.
- Ensure that outsourcing R&D takes place in permissible jurisdictions; watch for “treatment excluding clinical trials” clauses.
- Time investments so that acquisitions occur within the eligible period (until **March 31, 2028** for many measures).
- Track legislative changes annually: some incentives are temporary and subject to expiration or adjustment.
## Key Actions for Entity Planners
1. Audit your planned capital investments and R&D projects for eligibility with FY2026 measures.
2. Engage METI early for approvals where needed.
3. Model tax impact comparing depreciation vs credit.
4. Maintain compliance to claim overseas R&D credits.
Companies that align operations with these new tax incentives by accounting, structuring and planning in advance stand to realize meaningful savings, enhanced competitiveness, and stronger global positioning under Japan’s tax reforms.